Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 4, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions

Glioma Glioblastoma Multiforme

Interventions

DRUG

123I-ATT001

Trial Locations (2)

RECRUITING

University College London Hosptial, London

NOT_YET_RECRUITING

University Hospital Southampton, Southampton

All Listed Sponsors

lead

Theragnostics Ltd

INDUSTRY